Skip to main content
Premium Trial:

Request an Annual Quote

Prudential Begins Genomics Coverage; Myriad Takes a Beating

NEW YORK, Feb. 21 - Prudential Securities on Thursday said that it has begun covering Celera Genomics, Human Genome Sciences, Millennium Pharmaceuticals, Myriad Genetics, and Tularik.

Analyst Christopher Raymond set the following price targets: Celera, $33; HGS, $28; Millennium, $38; Myriad, $25; and Tularik, $22, according to Reuters.


The analyst rated Myriad a 'sell,' Celera and Millennium a 'buy,' and HGS and Tularik a 'hold.' He said that Myriad presents "significant commercial, collaborative and commercial risk" in the near term, and that its genetic tests will fall flat among investors.

The market quickly responded: Myriad shares fell $3.84, or close to 10 percent, to $35.15 in mid-afternoon trading. Millennium inched up $.38 to $20.46, Celera jumped 60 cents to $21.34, Tularik dipped $.38 to $18.81, and HGS gained $.59 to sell at $24.62. All companies trade on the Nasdaq.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.